Project Details
Description
PROJECT SUMMARY/ABSTRACT
Understanding the causes and mechanisms underlying circadian rhythm disruptions that are associated with
fatigue during cancer treatment remains unclear. This current deficiency means that successful cancer treat-
ment falls short of its potential and prior quality-of-life remains elusive for patients. Our long-term goal is to im-
prove debilitating behavioral sequelae in cancer patients, thus improving quality-of-life, other comorbidities,
and mortality. Thus, the overall objective here is to establish the potential role of circadian disruption as a fun-
damental pathway by which chemotherapy promotes cancer-associated fatigue. Indeed, robust circadian rhyth-
micity of virtually all physiology is extremely well-conserved; desynchrony of these rhythms leads to negative
health and behavioral consequences. The central hypothesis is that chemotherapy-induced inflammation inhib-
its SCN function leading to fatigue. The rationale for this work is that circadian circuitry disruption is an under-
studied, relevant pathway in psycho-oncology research that could elucidate mechanisms and new, rhythm-fo-
cused interventions. Three specific aims are proposed to test the central hypothesis using our novel breast
cancer “survivor” mouse model. Aim 1 will determine the ability of the master clock to entrain after chemother-
apy. Behavioral SCN rhythm adaptations to environmental challenges will be assessed. Aim 2 will identify the
role of central inflammation in master clock disruptions after chemotherapy. The role of chemotherapy-induced
neuroinflammation on SCN molecular and behavioral rhythms will be quantified. The potential resolution of fa-
tigue will also be assessed. Aim 3 will determine the role of circadian disruption in chemotherapy-induced fa-
tigue. Genetic and pharmacological SCN timing manipulations will precede a battery of behavioral assess-
ments of the physical, motivation, and cognitive components of fatigue. In vivo and ex vivo circadian timing ap-
proaches combined with systems-, cellular-, and molecular-level analyses will pinpoint the effects of two regi-
mens of chemotherapy on master oscillator circadian circuitry relevant to cancer-related behavioral comorbidi-
ties. The proposed research is conceptually innovative because using circadian approaches is new to psycho-
oncology. It is also technically innovative by way of the superior translational model and the circadian genetic
and pharmacological techniques planned. This research will result in essential new knowledge about how com-
mon cancer treatments affect the pacemaker, which is crucial to extensive downstream physiology and behav-
ior (i.e., beyond fatigue). Results will provide much needed evidence to make circadian-based approaches
standard in clinical practice, as well as inform the design of novel circadian-directed pharmacological and non-
pharmacological interventions. This research is applicable to other cancers and in non-oncological populations
treated with chemotherapy (e.g., stem cell transplant, lupus).
Status | Active |
---|---|
Effective start/end date | 01/23/23 → 12/31/24 |
Funding
- National Cancer Institute: $548,150.00
- National Cancer Institute: $72,094.00
- National Cancer Institute: $480,732.00
- National Cancer Institute: $31,509.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.